

ASIATIC LABORATORIES LIMITED

Registered and Corporate Office: 42-43, Siddeshawri Circular Road, Treasure Island (5th Floor), Shantinagar, Dhaka-1217, Bangladesh, **Telephone:** +88-02-48317908, **Fax:** +88-02-8311633, **Website:** www.Asiaticpharma.com

PRICE SENSITIVE INFORMATION

This is for kind information of the valued shareholders of Asiatic Laboratories Limited and all concerned that, the Board of Directors of the company in its 247th Board of Directors meeting held on **Thursday, February 13, 2025** at 5:00 pm at the registered and corporate office 42-43, Siddeshawri Circular Road, Treasure Island (5th Floor), Shantinagar, Dhaka-1217, Bangladesh has approved the Un-audited Financial Statements for the period/2nd Quarter ended **31 December, 2024**.

The following information published as per the Regulatory Requirement based on the approved Un-audited Financial Statements for the period/2nd Quarter (Q-2) ended **31st December, 2024**.

As per the Un-audited Financial Statements for the period/2nd Quarter (Q-2) ended 01 July 2024 to 31 December, 2024:

(Figure in BDT)

Sl. No.	Particulars	01-07-2024 to 31-12-2024	01-07-2023 to 31-12-2023	01-10-2024 to 31-12-2024	01-10-2023 to 31-12-2023
01.	Net Profit after Tax	118,348,260	148,794,250	88,260,570	59,841,896
02.	Earnings Per Share (EPS)	0.96	1.54	0.72	0.62
03.	Net Operating Cash Flows Per Share (NOCFPS)	0.87	1.19	N/A	N/A

Sl. No.	Particulars	As on 31 Dec. 2024	As on 30 Jun, 2024
04.	Net Asset Value (NAV) with Revaluation Surplus	6,481,343,642	6,435,560,348
05.	Net Asset Value (NAV) without Revaluation Surplus	4,859,267,371	4,811,422,220
06.	Net Asset Value Per Share (NAVPS) with Revaluation Surplus	52.95	52.58
07.	Net Asset Value Per Share (NAVPS) without Revaluation Surplus	39.70	39.31

Significant deviation in EPS, NAVPS and NOCFPS:

A) **EPS** has been slightly changed due to a change of the Net Profit after Tax, deviation in deferred tax income/(expenses) as well as increase of operating expenses, Financial Expenses and an increase in the number of Ordinary Shares for the period ended on **31 December, 2024** compared to the preceding similar period ended on **31 December, 2023** of the Company.

B) **NAVPS** with Revaluation Surplus has been increased due to added net profit after tax as of **31 December, 2024**, NAVPS without Revaluation Surplus has been increased due to added net profit after tax as of **31 December, 2024**.

C) **NOCFPS** has decreased due to a decrease in collection from customers and an increase in the number of Ordinary Shares for the period ended on **31 December, 2024** compared to the preceding similar period ended on **31 December, 2023** of the Company.

D) Noted that the EPS, NOCFPS and NAVPS for the period ended on **31 December, 2024** have been calculated considering **122,393,455** number of Ordinary shares.

Thanking you,
For and on behalf of the Board of Directors of
Asiatic Laboratories Limited



Ishtiaq Ahmed

Company Secretary

Dated: 12 February, 2024

Place: Dhaka